Peconic provides high quality and cost-effective ChIP-exo and ChIP-seq laboratory and data analysis methods to the epigenomic research community.
Epigenomics, the science of gene regulation on a global scale, is rapidly growing and has been called the new frontier of biotechnology and personalized medicine. Understanding why and how genes are regulated has significant value in medical research, drug development, bioproduct development, and many other fields. By offering ChIP-exo and ChIP-seq as services, Peconic aims to broaden the tools available to researchers while also reducing their costs and risk.
With years of experience performing and optimizing our ChIP assays, we have developed effective and efficient ChIP-exo and ChIP-seq procedures. Assays we conduct provide high resolution data, helping our customers drive towards new knowledge and solutions. Our results are presented in an easy-to-use and interpret format, enabling our customers to quickly disseminate new knowledge.
From sample preparation to data construction, our many quality controls help us provide our customers with high quality data. However, as with any such lab technique, there is no guarantee that the DNA samples and antibodies are experimentally compatible. Our low-priced validation service assesses the ChIP-exo and/or ChIP-seq compatibility of submitted DNA and antibodies. Researchers then have the option to acquire the bioinformatics reports of their choosing. Our goal is to help researchers solve some of the most complex biological problems that currently exist while reducing the risk associated with experimental procedures.
We have worked with many academic researchers throughout the world to create new knowledge in the area of epigenomics.
Peconic provides end-to-end ultra-high resolution ChIP-seq services. We start with your antibody and cell pellet and deliver >20 million paired-end reads per sample, along with controls, statistics, and data analysis at near single-bp resolution.
Chromatin immunoprecipitation, or “ChIP”, is a means by which the genomic binding locations for a protein can be identified. This involves formaldehyde-based crosslinking of proteins to DNA to covalently trap proteins at their physiologically-bound locations in vivo. Genomic binding sites are separated from other sites by sonication, which shears chromosomes into small fragments of ~200-1000 bp. The protein of interest is then purified using immobilized antibodies directed against the protein. The random cleavage of DNA by the sonication process limits mapping resolution to about ±100 bp. To improve this resolution, ChIP-exo employs lambda exonuclease to trim the randomly cleaved ends up to the point of where the protein is crosslinked to DNA, thereby diminishing the uncertainty to about a few base pairs. Since the trimming is exclusively in the 5’- 3’ direction, DNA sequences downstream (more 3’) of the exonuclease block site remain intact, and thus are sufficiently long to allow unique identification by deep sequencing.
Details of the method can be found in a publication by H.S. Rhee and B.F. Pugh in Cell 2011, 147(6):1408-1419 titled “Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution.” It should be noted that ChIP-exo is an experimental method with many complicated steps that may fail for technical reasons, or because the protein of interest may not "ChIP" very well.
Peconic, LLC has not received any reviews.
Peconic, LLC has not received any endorsements.